Cixutumumab
Cixutumumab Uses, Dosage, Side Effects, Food Interaction and all others data.
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
| Trade Name | Cixutumumab |
| Generic | Cixutumumab |
| Cixutumumab Other Names | Cixutumumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How Cixutumumab works
Cixutumumab is a fully human monoclonal antibody that specifically targets the type 1 human insulin-like growth factor receptor (IGF-IR). Tumors have receptors for the insulin-like growth factor-1 (IGF-I), and it is thought that the presence of these receptors cause tumors to grow. Cixutumumab attaches to the receptors and may inhibit the growth of cancer cells.
Half Life
148 h (3 mg/kg dose level) 209 h (6mg/kg dose level)
Innovators Monograph
You find simplified version here Cixutumumab
